"BRCA2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)
Descriptor ID |
D024682
|
MeSH Number(s) |
D12.776.313.249 D12.776.624.776.101 D12.776.660.105
|
Concept/Terms |
BRCA2 Protein- BRCA2 Protein
- FANCD1 Protein
- Fanconi Anemia Complementation Group D1 Protein
- Fanconi Anemia Group D1 Protein
- BRCA2 Gene Product
- Breast Cancer 2 Gene Product
- Fanconi Anemia Group D1 Complementing Protein
- Breast Cancer 2 Protein
|
Below are MeSH descriptors whose meaning is more general than "BRCA2 Protein".
Below are MeSH descriptors whose meaning is more specific than "BRCA2 Protein".
This graph shows the total number of publications written about "BRCA2 Protein" by people in this website by year, and whether "BRCA2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 0 | 6 | 6 |
2001 | 0 | 2 | 2 |
2002 | 1 | 0 | 1 |
2004 | 1 | 1 | 2 |
2005 | 0 | 2 | 2 |
2007 | 2 | 1 | 3 |
2008 | 1 | 1 | 2 |
2009 | 3 | 0 | 3 |
2010 | 2 | 0 | 2 |
2011 | 4 | 0 | 4 |
2012 | 2 | 0 | 2 |
2013 | 0 | 1 | 1 |
2014 | 3 | 1 | 4 |
2015 | 3 | 0 | 3 |
2016 | 3 | 0 | 3 |
2017 | 3 | 2 | 5 |
2018 | 6 | 1 | 7 |
2019 | 9 | 5 | 14 |
2020 | 4 | 3 | 7 |
2021 | 8 | 1 | 9 |
2022 | 0 | 2 | 2 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "BRCA2 Protein" by people in Profiles.
-
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023 Mar 20; 41(9):1703-1713.
-
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. Commun Biol. 2022 10 06; 5(1):1061.
-
Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay. Clin Cancer Res. 2022 09 01; 28(17):3742-3751.
-
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. Gynecol Oncol. 2021 10; 163(1):130-133.
-
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. J Clin Oncol. 2021 11 01; 39(31):3430-3440.
-
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genet Med. 2021 09; 23(9):1726-1737.
-
Cancer-causing BRCA2 missense mutations disrupt an intracellular protein assembly mechanism to disable genome maintenance. Nucleic Acids Res. 2021 06 04; 49(10):5588-5604.
-
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia. 2021 11; 35(11):3245-3256.
-
Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance. Am J Hum Genet. 2021 03 04; 108(3):458-468.
-
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.